Company Overview and News

4
Emerald Health Therapeutics Welcomes Historic Passing of Bill C-45 to Legalize Adult-Use Cannabis in Canada

2018-06-19 globenewswire
VICTORIA, British Columbia, June 19, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (TSXV:EMH) (OTCQX:EMHTF) (Emerald) today applauds the Canadian government’s historic passing of Bill C-45 (Cannabis Act) to end Canada’s near century-long prohibition of recreational cannabis and usher in a new era of cannabis regulation.
EMH TBQBF EMHTF

4
4 Marijuana-Related Companies That Just Raised Capital

2018-05-31 seekingalpha
We wanted to walk marijuana investors through the four companies, why they raised money, and more.
EMH TBQBF EMHTF VFFIF

28
Cannabis Sector Back in the Red for Week Ended May 25

2018-05-29 marketrealist
Last week, which ended on May 25, cannabis sector ETFs slipped into negative territory sequentially, with the Horizons Marijuana Life Sciences ETF (HMMJ) closing ~1% lower than the closing on May 18. The ETFMG Alternative Harvest ETF (MJ) fell ~1.7%, and the Horizons Emerging Marijuana Growers Index ETF (HMJR) fell ~1.7%. The Evolve Marijuana ETF (SEED) fell 1.4%.
TWMJF EMH ACB MJ TBQBF EMHTF WEED ACBFF MJX OGRMF CGC OGI

4
Emerald Health Therapeutics Announces $16.8 Million Prospectus Sale; Concurrent Secondary Sale

2018-05-15 globenewswire
VICTORIA, British Columbia, May 15, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (TSXV:EMH) ("Emerald" or the “Company”) has entered into a binding term sheet with a single Canadian institutional accredited investor (the “Investor”) under which the Investor has agreed, subject to certain customary conditions, to purchase 4,000,000 units of the Company (the “Units”) at a price of $4.20 per Unit for total gross proceeds of $16,800,000 (the “Offering”).
EMH TBQBF EMHTF VFFIF

4
Emerald Health Therapeutics Names DDB Canada Agency of Record

2018-04-20 globenewswire
VICTORIA, British Columbia, April 20, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics Inc. (“Emerald”) (TSX-V:EMH) (OTCQX:EMHTF) today announced DDB Canada’s Vancouver office its agency of record (AOR) following a national search managed by Reynolds & Fyshe. As agency of record, DDB Canada Vancouver and its integrated suite of marketing specialist disciplines, Twice, TRACKDDB, DDB Public Relations, TracyLocke Canada and Tribal Worldwide, will be providing a full range of seamlessly integrated communications services.
EMH TBQBF EMHTF

4
Emerald Health Therapeutics Expands Strategic Investment in VANC

2018-04-17 globenewswire
VANCOUVER, British Columbia, April 17, 2018 (GLOBE NEWSWIRE) -- VANC Pharmaceuticals Inc. (“VANC”) announced today that it has entered into a supply and distribution agreement (“Distribution Agreement”) with an affiliate of Emerald Health Therapeutics, Inc. (TSXV:EMH) (OTCQX:EMHTF) (“Emerald”), pursuant to which VANC was granted rights to sell and distribute certain proprietary endocannabinoid-supporting products in Canada to licensed pharmacies.
EMH TBQBF EMHTF NUVPF VFFIF NPH

7
GW Pharma's Cannabinoid-Based Epilepsy Position Continues To Strengthen

2018-04-02 seekingalpha
Childhood Epilepsy solutions are just the first phase in a range of treatments for GW Pharma.
NMUS EMH TBQBF EMHTF INSY

4
TheBaron VII: Tough Market Movement Spells Opportunity

2018-03-28 seekingalpha
The overall portfolio had a weak month due mainly to one company's continued share price weakness, with slight moves downwards in most of the portfolio.
EMH MGRUF DR TBQBF EMHTF NWHUF CSEAF VFFIF DR.DB.A MFCSF

4
DMG CEO Report Q1

2018-03-27 globenewswire
DMG Blockchain Solutions Announces Q1 Progress: Cryptocoin Mining Service Capacity Sells Out, Up to a 85 Megawatt Mine Construction Underway, Closes First M&A Deal, Strategic Partnerships Inked
MFTGF EMH NXT TBQBF EFN GO EMHTF

4
DMG CEO Report Q1

2018-03-21 globenewswire
DMG Blockchain Solutions Announces Q1 Progress: Cryptocoin Mining Service Capacity Sells Out, Up to a 85 Megawatt Mine Construction Underway, Closes First M&A Deal, Strategic Partnerships Inked
MFTGF EMH NXT TBQBF EFN GO EMHTF

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

7h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

8h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Silicon Investor Message Boards

This table lists all message boards related to TSXV:EMH / Emerald Health Therapeut on message board site Silicon Investor.

Remington-Hall (REMH)